Menu

Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
📰

Revolution Medicines’ pancreatic cancer drug has stunning commercial debut

Business - Latest - Google News·11 days ago
#frXoKWzT
#world#news#statnews#biotech#adam
Reading 0:00
15s threshold

Nov. 5, 2026

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard , a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

The commercial debut of Revolution Medicines’ pancreatic cancer drug Rasonque was eye-popping and jaw-dropping: $198 million in sales in just five weeks following the U.S. approval of the groundbreaking pan-RAS inhibitor. More than 5,000 patients have already been treated with the drug, the company said Wednesday evening.

“The U.S.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.